**For more on the FDA approval of the Pfizer vaccine, watch below.
That’s according to clinical trial studies in people previously vaccinated with the single-shot vaccine, the company said in a press release.
According to Johnson & Johnson, the booster dose of the vaccine “generated a rapid and robust increase in spike-binding antibodies” in participants between the ages of 18 and 55 and in those 65 years and older.
“We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. “We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.”
Johnson & Johnson said it is working with the FDA, CDC and other health authorities regarding booster shots, and ongoing trials are underway.